STTK trades 109.2% below Wall Street's consensus target of $13.20.
Last 12 months price action with 12-month analyst target path
The base valuation assumes STTK achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Shattuck Labs, Inc. (STTK) has a Wall Street consensus price target of $13.20, based on estimates from 9 covering analysts. With the stock currently trading at $6.31, this represents a potential upside of +109.2%. The company has a market capitalization of $570M.
Analyst price targets range from a low of $7.00 to a high of $18.00, representing a 83% spread in expectations. The median target of $14.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, STTK trades at a trailing P/E of -9.0x. Analysts expect EPS to grow -21.7% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 RCUSArcus Biosciences, Inc. | $3.2B | $25.06 | $40.00 | +59.6% | Buy | — | 18 |
 IMVTImmunovant, Inc. | $7.0B | $34.00 | $40.00 | +17.6% | Buy | — | 23 |
 AGENAgenus Inc. | $354M | $8.50 | $25.00 | +194.1% | Buy | 11.0x | 11 |
 NKTXNkarta, Inc. | $204M | $2.85 | $9.00 | +215.8% | Buy | — | 12 |
 CRISCuris, Inc. | $2M | $0.88 | — | — | Buy | — | 18 |
 TGTXTG Therapeutics, Inc. | $8.8B | $57.52 | $80.50 | +40.0% | Buy | 57.3x | 13 |
 FATEFate Therapeutics, Inc. | $272M | $2.33 | $5.63 | +141.6% | Buy | — | 31 |
 ALNYAlnylam Pharmaceuticals, Inc. | $33.3B | $249.59 | $347.33 | +39.2% | Buy | 37.4x | 52 |
 KYMRKymera Therapeutics, Inc. | $9.5B | $115.81 | $136.75 | +18.1% | Buy | — | 27 |
 RVMDRevolution Medicines, Inc. | $42.5B | $199.86 | $247.00 | +23.6% | Buy | — | 24 |
Quick answers to the most common questions about buying STTK stock.
The consensus Wall Street price target for STTK is $13.2, representing 109.2% upside from the current price of $6.31. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
STTK has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $13.2 implies 109.2% upside from current levels.
STTK's current price is $6.31 with a consensus target of $13.2 (109.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $18 for STTK, while the most conservative target is $7. The consensus of $13.2 represents the median expectation. These targets typically reflect 12-month expectations.
STTK is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month STTK stock forecast based on 9 Wall Street analysts shows a consensus price target of $13.2, with estimates ranging from $7 (bear case) to $18 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on STTK, with a "Buy" consensus rating and $13.2 price target (109.2% upside). 9 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
STTK analyst price targets range from $7 to $18, a 83% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $13.2 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.